Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials
Drug Science Policy and Law January 1, 2022 Jeremy Roscoe, Olivia Lozy 30 citations
A systematic review of 52 clinical trials found that none reported psilocybin to be unsafe when administered under medical supervision. Twenty-seven of the trials suggested that psilocybin is safe to administer in a controlled medical setting. The review assessed whether psilocybin meets the schedule I criterion of lacking accepted safety for use under medical supervision, and the evidence from these trials does not support that designation. No adverse events or safety concerns were reported that would indicate the drug is unsafe when given by a medical professional.